KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Cash from Discontinued OperationsCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Other Working Capital Changes (2016 - 2025)

Historic Other Working Capital Changes for TherapeuticsMD (TXMD) over the last 16 years, with Q3 2025 value amounting to -$529000.0.

  • TherapeuticsMD's Other Working Capital Changes fell 539000.0% to -$529000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.5 million, marking a year-over-year decrease of 1467000.0%. This contributed to the annual value of -$1.9 million for FY2024, which is 203000.0% down from last year.
  • As of Q3 2025, TherapeuticsMD's Other Working Capital Changes stood at -$529000.0, which was down 539000.0% from -$370000.0 recorded in Q2 2025.
  • TherapeuticsMD's Other Working Capital Changes' 5-year high stood at $2.3 million during Q3 2023, with a 5-year trough of -$3.2 million in Q4 2023.
  • For the 5-year period, TherapeuticsMD's Other Working Capital Changes averaged around -$229631.6, with its median value being -$56000.0 (2024).
  • Its Other Working Capital Changes has fluctuated over the past 5 years, first soared by 136193.55% in 2023, then plummeted by 539000.0% in 2025.
  • Over the past 5 years, TherapeuticsMD's Other Working Capital Changes (Quarter) stood at -$692000.0 in 2021, then soared by 67.34% to -$226000.0 in 2022, then plummeted by 1333.63% to -$3.2 million in 2023, then surged by 98.27% to -$56000.0 in 2024, then tumbled by 844.64% to -$529000.0 in 2025.
  • Its Other Working Capital Changes was -$529000.0 in Q3 2025, compared to -$370000.0 in Q2 2025 and -$502000.0 in Q1 2025.